See more : Mystic Electronics Limited (MYSTICELE.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Chembio Diagnostics, Inc. (CEMI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Chembio Diagnostics, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Cardtronics plc (CATM) Income Statement Analysis – Financial Results
- Hennessy Capital Investment Corp. V (HCICU) Income Statement Analysis – Financial Results
- M&T 1997, a.s. (KLIKY.PR) Income Statement Analysis – Financial Results
- Astrocast SA (ASTRO.OL) Income Statement Analysis – Financial Results
- QYOU Media Inc. (QYOU.V) Income Statement Analysis – Financial Results
Chembio Diagnostics, Inc. (CEMI)
About Chembio Diagnostics, Inc.
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, rickettsia, and Burkholderia diseases. The company sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, and DPP trademarks, as well as sells its products directly through distributors to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. It has collaboration agreements with Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, The Oswaldo Cruz Foundation, and the Foundation for Innovative New Diagnostics, as well as U.S. government agencies, such as Centers for Disease Control and Prevention, the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services, and the U.S. Department of Agriculture. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 48.34M | 36.93M | 30.45M | 34.46M | 33.41M | 24.02M | 17.87M | 24.26M | 27.65M | 29.55M | 25.61M | 19.39M | 16.70M | 13.83M | 11.05M | 9.23M | 6.50M | 3.94M | 3.31M | 0.00 | 0.00 | 0.00 | 1.00 |
| Cost of Revenue | 38.58M | 34.50M | 23.87M | 22.39M | 21.43M | 12.92M | 9.42M | 13.77M | 16.83M | 17.25M | 14.82M | 10.00M | 8.60M | 7.97M | 7.20M | 5.37M | 4.49M | 2.61M | 2.49M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 9.76M | 2.43M | 6.58M | 12.07M | 11.98M | 11.09M | 8.45M | 10.49M | 10.81M | 12.30M | 10.79M | 9.39M | 8.10M | 5.86M | 3.85M | 3.86M | 2.02M | 1.33M | 820.34K | 0.00 | 0.00 | 0.00 | 1.00 |
| Gross Profit Ratio | 20.19% | 6.58% | 21.60% | 35.02% | 35.86% | 46.20% | 47.30% | 43.23% | 39.12% | 41.63% | 42.13% | 48.43% | 48.49% | 42.36% | 34.86% | 41.84% | 31.01% | 33.80% | 24.81% | 0.00% | 0.00% | 0.00% | 100.00% |
| Research & Development | 7.07M | 12.49M | 9.51M | 8.54M | 8.53M | 8.56M | 8.43M | 6.38M | 4.83M | 5.83M | 4.49M | 4.88M | 2.59M | 2.88M | 2.61M | 1.91M | 1.40M | 1.36M | 1.43M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.15M | 5.73M | 4.48M | 3.55M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 44.28K | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.51M | 1.78M | 1.01M | 1.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 765.00 | 0.00 | 0.00 |
| SG&A | 24.28M | 24.84M | 21.04M | 16.14M | 11.10M | 9.02M | 7.60M | 7.66M | 7.50M | 5.49M | 4.85M | 3.42M | 2.94M | 2.66M | 3.32M | 4.83M | 5.20M | 3.24M | 2.49M | 3.11K | 45.05K | 6.73K | 128.83K |
| Other Expenses | -1.18M | -10.89M | -2.02M | 0.00 | 0.00 | 0.00 | 0.00 | -4.81K | -5.71K | 7.50K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 30.16M | 26.44M | 28.53M | 24.68M | 19.63M | 17.58M | 16.02M | 14.04M | 12.36M | 11.30M | 9.34M | 8.30M | 5.53M | 5.54M | 5.92M | 6.74M | 6.61M | 4.63M | 3.92M | 7.12K | 47.02K | 6.73K | 130.77K |
| Cost & Expenses | 68.74M | 60.93M | 52.40M | 47.07M | 41.05M | 30.50M | 25.44M | 27.81M | 29.20M | 28.54M | 24.16M | 18.30M | 14.13M | 13.52M | 13.12M | 12.11M | 11.10M | 7.24M | 6.41M | 7.12K | 47.02K | 6.73K | 130.77K |
| Interest Income | 0.00 | 0.00 | 0.00 | -846.83K | 49.50K | 25.43K | 25.55K | 2.41K | 5.84K | 5.78K | 7.91K | 6.30K | 4.15K | 9.03K | 34.40K | 145.29K | 29.53K | 39.80K | 8.13K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 382.00K | 2.91M | 2.84M | -846.83M | 0.00 | 2.95K | 0.00 | 836.00 | 0.00 | 335.00 | 9.50K | 18.62K | 14.73K | 10.60K | 8.32K | 16.88K | 386.90K | 15.68K | 190.56K | 0.00 | 635.00 | 0.00 | 14.00 |
| Depreciation & Amortization | 5.79M | 2.93M | 2.70M | 721.47K | 337.65K | 1.28M | 1.14M | 1.37M | 739.30K | 607.82K | 523.28K | 437.83K | 283.74K | 362.34K | 345.39K | 283.36K | 209.54K | 98.51K | 109.97K | 4.01K | 367.00 | 63.41K | 176.00 |
| EBITDA | -14.61M | -21.07M | -19.25M | -11.89M | -7.31M | -5.18M | -6.41M | -2.18M | -810.82K | 1.63M | 1.45M | 1.53M | 2.86M | 688.70K | -1.69M | -2.71M | -4.33M | -3.20M | -3.18M | -11.62K | -46.65K | 56.67K | -132.51K |
| EBITDA Ratio | -30.23% | -57.07% | -63.23% | -34.49% | -21.87% | -21.57% | -35.86% | -9.00% | -2.93% | 5.50% | 5.67% | 7.90% | 17.13% | 4.98% | -15.30% | -29.40% | -66.58% | -81.19% | -96.20% | 0.00% | 0.00% | 0.00% | -13,251,300.00% |
| Operating Income | -20.40M | -24.01M | -21.95M | -12.61M | -7.65M | -6.48M | -7.57M | -3.55M | -1.55M | 1.00M | 1.45M | 1.09M | 2.57M | 317.33K | -2.07M | -2.88M | -4.60M | -3.30M | -3.10M | -7.12K | -47.02K | -6.73K | -130.77K |
| Operating Income Ratio | -42.21% | -65.01% | -72.08% | -36.58% | -22.88% | -26.99% | -42.37% | -14.65% | -5.61% | 3.40% | 5.67% | 5.61% | 15.41% | 2.29% | -18.74% | -31.16% | -70.68% | -83.69% | -93.87% | 0.00% | 0.00% | 0.00% | -13,076,900.00% |
| Total Other Income/Expenses | 381.80K | -9.96M | -2.84M | -846.83K | 49.50K | 22.49K | 25.55K | -3.24K | 132.00 | 12.94K | -1.58K | -12.33K | -14.50K | -8.27K | 121.90K | 249.27K | -398.83K | 45.99K | 186.90K | 8.51K | 0.00 | -63.41K | 1.92K |
| Income Before Tax | -23.26M | -33.97M | -25.98M | -14.18M | -7.93M | -6.46M | -7.55M | -3.56M | -1.55M | 1.02M | 1.45M | 1.08M | 2.56M | 309.06K | -1.95M | -2.63M | -5.00M | -3.25M | -2.92M | 1.39K | 0.00 | -70.14K | -128.85K |
| Income Before Tax Ratio | -48.11% | -91.98% | -85.31% | -41.13% | -23.75% | -26.90% | -42.23% | -14.67% | -5.61% | 3.44% | 5.66% | 5.55% | 15.32% | 2.23% | -17.64% | -28.46% | -76.82% | -82.52% | -88.22% | 0.00% | 0.00% | 0.00% | -12,884,900.00% |
| Income Tax Expense | 34.41K | -62.05K | -456.79K | -500.29K | -67.52K | -88.31K | 5.80M | -1.16M | -412.92K | 486.95K | 509.24K | -5.13M | 45.82K | 10.60K | 8.32K | -249.27K | 398.83K | -24.12K | -4.47K | -8.51K | 635.00 | 2.67K | -1.91K |
| Net Income | -23.29M | -33.90M | -25.52M | -13.68M | -7.87M | -6.37M | -13.35M | -2.40M | -1.14M | 530.82K | 941.28K | 6.21M | 2.51M | 309.06K | -1.95M | -2.63M | -5.00M | -3.25M | -3.10M | 1.39K | -47.65K | -72.82K | -128.86K |
| Net Income Ratio | -48.18% | -91.81% | -83.81% | -39.68% | -23.54% | -26.53% | -74.69% | -9.88% | -4.11% | 1.80% | 3.68% | 32.02% | 15.05% | 2.23% | -17.64% | -28.46% | -76.82% | -82.52% | -93.74% | 0.00% | 0.00% | 0.00% | -12,886,400.00% |
| EPS | -0.96 | -1.40 | -1.34 | -0.81 | -0.54 | -0.52 | -1.26 | -0.25 | -0.12 | 0.06 | 0.12 | 0.79 | 0.32 | 0.04 | -0.25 | -1.44 | -3.88 | -3.38 | -4.15 | 0.18 | -5.95 | -35.43 | -115.16 |
| EPS Diluted | -0.96 | -1.40 | -1.34 | -0.81 | -0.54 | -0.52 | -1.26 | -0.25 | -0.12 | 0.06 | 0.11 | 0.73 | 0.32 | 0.03 | -0.25 | -1.44 | -3.88 | -3.38 | -4.15 | 0.18 | -5.95 | -35.43 | -115.16 |
| Weighted Avg Shares Out | 24.30M | 24.30M | 19.09M | 16.95M | 14.43M | 12.30M | 10.62M | 9.63M | 9.53M | 8.99M | 7.99M | 7.87M | 7.76M | 7.74M | 7.66M | 1.83M | 1.29M | 963.22K | 745.85K | 132.89K | 136.19K | 34.94K | 19.02K |
| Weighted Avg Shares Out (Dil) | 24.30M | 24.30M | 19.09M | 16.95M | 14.43M | 12.30M | 10.62M | 9.63M | 9.53M | 9.52M | 8.61M | 8.56M | 8.87M | 9.38M | 7.66M | 1.83M | 1.29M | 963.22K | 745.85K | 132.89K | 136.19K | 34.94K | 19.02K |
Berkarya anulir seluruh rekomendasi pilkada di Indonesia termasuk NTB
Wasekjen Gerindra paparkan mekanisme Prabowo jadi Caketum tunggal
Kessler Topaz Meltzer & Check, LLP - Important Deadline Reminder for Chembio Diagnostics, Inc. Investors
Gerindra akan gelar KLB kukuhkan Prabowo jadi ketua umum
Author petitions DPP to prosecute Tourism Ministry for copyright infringement
Lawyer demands Sri Ram’s letter of appointment
DPP withdraws charges against MP Francis Zaake
Banker Gets Son Back After Four Years’ Battle With Father-In-Law | Naija News
Ketua DPRD Kabupaten Bekasi diganti?
Source: https://incomestatements.info
Category: Stock Reports